Lakewood-Amedex Biotherapeutics, Inc. (LABT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
8031 Cooper Creek Blvd., Unit 103
University Park, FL 34201
United States of America (the)
Phone
1-941-225-2515
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
April 23, 2026
| Name | Title | Pay | Year Born |
| Kelvin Cooper | CEO, SVP of Research & Development and Director | 190,417 | 1956 |
| Peter F. Ceccacci | CFO & VP of Administration | 160,000 | 1955 |
| Thomas Balzer | Chief Medical Officer & SVP of Clinical Development | 177,917 | 1960 |
| Tara Endress | Project Manager & Accounting Manager | 0 | N/A |
| Daniel Kontoh-Boateng | Investor Relations | 0 | N/A |
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.